Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Conditions
Pancreatic Cancer · Pancreatic Cancer Metastatic · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Pancreatic Ductal Adenocarcinoma (PDAC) · Pancreatic Adenocarcinoma Metastatic · Pancreatic Adenocarcinoma · Pancreatic Adenosquamous Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
Taylor Cancer Research Center, Maumee, Ohio, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
SCRI - Texas Oncology Dallas, Dallas, Texas, United States
Contact: Study coordinator (Christine Terraciano) · christine.terraciano@usoncology.com · 214-370-1000Virginia Cancer Specialists, Fairfax, Virginia, United States
Virginia Mason Medical Center, Seattle, Washington, United States
Wakayama Medical University Hospital, Wakayama, Japan
Yamaguchi University Hospital, Yamaguchi, Japan